Smart pH-sensitive and sequentially controlled drug delivery system based on PLGA-PEG overcomes multidrug resistance in hepatocellular carcinoma by endocytosis-mediated energy dissipation and energy production decrease
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Drug Transport and Resistance Mechanisms · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229–263. https://doi.org/10.3322/caac.2183410.3322/caac.21834 ↗
2. Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R et al (2016) (2022) Cancer incidence and mortality in China, 2016 Cancer incidence and mortality in China. J Natl Cancer Center 2(1):1–910.1016/j.jncc.2022.02.002 ↗
3. Zhong B, Fan W, Guan JJ, Peng Z, Jia Z, Jin H et al (2025) Combination locoregional and systemic therapies in hepatocellular carcinoma. Lancet Gastroenterol Hepatol 10(4):369. https://doi.org/10.1016/S2468-1253(24)00247-410.1016/S2468-1253(24)00247-4 ↗
4. Dudzinski SO, Newman NB, Mcintyre J, Engineer R, Sanford NN, Wo JY et al (2025) Emerging evidence-based role for external-beam radiation therapy in hepatocellular carcinoma. Lancet Gastroenterol Hepatol 10(4):387. https://doi.org/10.1016/S2468-1253(24)00267-X10.1016/S2468-1253(24)00267-X ↗
5. Zheng J, Wang S, Xia L, Sun Z, Chan KM, Bernards R et al (2025) Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther 10(1):35–43. https://doi.org/10.1038/s41392-024-02075-w10.1038/s41392-024-02075-w ↗
6. Pinter M, Fulgenzi CAM, Pinato DJ, Scheiner B (2025) Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction. Gut 74(7):1178–1188. https://doi.org/10.1136/gutjnl-2025-33492810.1136/gutjnl-2025-334928 ↗
7. Wu H, Lv S, Zhang R, Gu L, Xu J, Li C et al (2025) Next-generation flexible embolic systems: targeted transarterial chemoembolization strategies for hepatocellular carcinoma. Adv Mater 37(24):e2503971. https://doi.org/10.1002/adma.20250397110.1002/adma.202503971 ↗
8. Wang K, Zhong D, Yang L, Zeng C, Hu Q, Zhou M et al (2025) Microalgae-based biodegradable embolic agent for the treatment of hepatocellular carcinoma through transarterial embolization. J Nanobiotechnology 23(1):218–234. https://doi.org/10.1186/s12951-025-03290-510.1186/s12951-025-03290-5 ↗
9. Lee SY, Choi JW, Hwang C, Park J, Karmakar M, Huh JW et al (2024) Intravascular casting radiopaque hydrogel systems for transarterial chemo/cascade catalytic/embolization therapy of hepatocellular carcinoma. Small 20(46):e2400287. https://doi.org/10.1002/smll.20240028710.1002/smll.202400287 ↗
10. Elfiky A, El-Guendy N, Badr AM, Mohammed MA, Wahab AHAA (2025) The role of FOXA1 and miR-212-3p in molecular modulation of doxorubicin resistance in liver cancer. Med Oncol 42(5):160. https://doi.org/10.1007/s12032-025-02686-510.1007/s12032-025-02686-5 ↗
11. Lv Y, Deng Z, Bi Q, Tang J, Chen H, Xie C et al (2022) Intratumoral Pi deprivation benefits chemoembolization therapy via increased accumulation of intracellular doxorubicin. Drug Deliv 29(1):1743–1753. https://doi.org/10.1080/10717544.2022.208138410.1080/10717544.2022.2081384 ↗
12. Wei J, Lu M, Wei T, Fleishman JS, Yu H, Chen X et al (2025) Overcoming cancer therapy resistance: from drug innovation to therapeutics. Drug Resist Updat 81:101229. https://doi.org/10.1016/j.drup.2025.10122910.1016/j.drup.2025.101229 ↗
13. Abdeljawaad KAA, Abdelrahman AHM, Sidhom PA, Tallima H, Shoeib T, Mekhemer GAH et al (2025) Potential P-glycoprotein (P-gp) inhibitors from SuperDRUG2 database toward reversing multidrug resistance in cancer treatment: database mining, molecular dynamics, and binding energy estimations. J Mol Graph Model 137:108997. https://doi.org/10.1016/j.jmgm.2025.10899710.1016/j.jmgm.2025.108997 ↗
14. Ibba R, Sestito S, Ambrosio FA, Marchese E, Costa G, Fiorentino FP et al (2024) Discovery of pyridoquinoxaline-based new P-gp inhibitors as coadjutant against multi drug resistance in cancer. Eur J Med Chem 276:116647. https://doi.org/10.1016/j.ejmech.2024.11664710.1016/j.ejmech.2024.116647 ↗
15. Dong J, Yuan L, Hu C, Cheng X, Qin J (2023) Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): an updated review. Pharm Ther (Oxford) 249:108488. https://doi.org/10.1016/j.pharmthera.2023.10848810.1016/j.pharmthera.2023.108488 ↗
16. Su Z, Dong S, Zhao S, Liu K, Tan Y, Jiang X et al (2021) Novel nanomedicines to overcome cancer multidrug resistance. Drug Resist Updat 58:100777. https://doi.org/10.1016/j.drup.2021.10077710.1016/j.drup.2021.100777 ↗
17. Schulz JA, Hartz AMS, Bauer B (2023) ABCB1 and ABCG2 regulation at the blood-brain barrier: potential new targets to improve brain drug delivery. Pharmacol Rev 75(5):815–853. https://doi.org/10.1124/pharmrev.120.00002510.1124/pharmrev.120.000025 ↗
18. Sawada R, Furugen A, Ueda A, Nishimura A, Umazume T, Narumi K et al (2025) Analysis of drug transporter expression in syncytiotrophoblast derived from human placental stem cells: expression and function of efflux transporters. Placenta 165:23–32. https://doi.org/10.1016/j.placenta.2025.03.02110.1016/j.placenta.2025.03.021 ↗
19. Fanizza F, Perottoni S, Boeri L, Donnaloja F, Negro F, Pugli F et al (2025) A gut–brain axis on-a-chip platform for drug testing challenged with donepezil. Lab Chip 25(7):1854–1874. https://doi.org/10.1039/D4LC00273C10.1039/D4LC00273C ↗
20. Liu Z, Du W, Wang Q, Wang Z, An J, Ma Y et al (2025) In vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments. Front Pharmacol 16:1530806. https://doi.org/10.3389/fphar.2025.153080610.3389/fphar.2025.1530806 ↗
21. Cascorbi I, Kim RB (2025) Deciphering the relative contribution of CYP3A4 versus P-glycoprotein for the shared substrate cyclosporine—commentary on Lown et al. Clin Pharmacol Ther 117(6):1546–1561. https://doi.org/10.1002/cpt.361910.1002/cpt.3619 ↗
22. Luo J, Huang C, Liao Z, Ma X, Si T, Chen H et al (2025) Unidirectional drug delivery and responsive release guided by nanofunnel-shaped heterojunction. Nano Lett 25(19):7853–7859. https://doi.org/10.1021/acs.nanolett.5c0061710.1021/acs.nanolett.5c00617 ↗
23. Niu Z, He J, Wang S, Xue B, Zhang H, Hou R et al (2025) Targeting glycolysis for treatment of breast cancer resistance: current progress and future prospects. Int J Biol Sci 21(6):2589–2605. https://doi.org/10.7150/ijbs.10980310.7150/ijbs.109803 ↗
24. Bianchi N, Ancona P, Aguiari G (2025) Molecular mechanisms of drug resistance in clear cell renal cell carcinoma. Cancers (Basel) 17(10):1613. https://doi.org/10.3390/cancers1710161310.3390/cancers17101613 ↗
25. Fan J, To KKW, Chen Z, Fu L (2023) ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance. Drug Resist Updat 66:100905. https://doi.org/10.1016/j.drup.2022.10090510.1016/j.drup.2022.100905 ↗
26. Dong J, Qin Z, Zhang W, Cheng G, Yehuda AG, Ashby CR (2020) Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update. Drug Resist Updat 49:100681. https://doi.org/10.1016/j.drup.2020.10068110.1016/j.drup.2020.100681 ↗
27. Pathak R, Halagali P, Tippavajhala VK, Dodakallanavar J, Ramachandra HD, Sharma H (2025) Recent advances in targeted nanocomposite-based therapeutics for cancer therapy. Curr Drug Res Rev. https://doi.org/10.2174/012589977536784825022606370010.2174/0125899775367848250226063700 ↗
28. Li X, Peng X, Zoulikha M, Boafo GF, Magar KT, Ju Y et al (2024) Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduct Target Ther 9(1):1. https://doi.org/10.1038/s41392-023-01668-110.1038/s41392-023-01668-1 ↗
29. Dechbumroong P, Hu R, Keaswejjareansuk W, Namdee K, Liang X (2024) Recent advanced lipid-based nanomedicines for overcoming cancer resistance. Cancer Drug Resist 7:24. https://doi.org/10.20517/cdr.2024.1910.20517/cdr.2024.19 ↗
30. Pan X, Ni S, Hu K (2024) Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma. Biomaterials 306:122481. https://doi.org/10.1016/j.biomaterials.2024.12248110.1016/j.biomaterials.2024.122481 ↗
31. Zhu C, Lv M, Song F, Zheng D, Liu C, Liu X et al (2023) Reversible covalent nanoassemblies for augmented nuclear drug translocation in drug resistance tumor. J Control Release 353:186–195. https://doi.org/10.1016/j.jconrel.2022.11.03110.1016/j.jconrel.2022.11.031 ↗
32. Zhou M, Li L, Li L, Lin X, Wang F, Li Q et al (2019) Overcoming chemotherapy resistance via simultaneous drug-efflux circumvention and mitochondrial targeting. Acta Pharm Sin B 9(3):615–625. https://doi.org/10.1016/j.apsb.2018.11.00510.1016/j.apsb.2018.11.005 ↗
33. Xiao Q, Zhao W, Wu C, Wang X, Chen J, Shi X et al (2022) Lemon-derived extracellular vesicles nanodrugs enable to efficiently overcome cancer multidrug resistance by endocytosis-triggered energy dissipation and energy production reduction. Adv Sci (Weinh) 9(20):e2105274. https://doi.org/10.1002/advs.20210527410.1002/advs.202105274 ↗
34. Hamadani CM, Dasanayake GS, Gorniak ME, Pride MC, Monroe W, Chism CM et al (2023) Development of ionic liquid-coated PLGA nanoparticles for applications in intravenous drug delivery. Nat Protoc 18(8):2509–2557. https://doi.org/10.1038/s41596-023-00843-610.1038/s41596-023-00843-6 ↗
35. Zöller K, To D, Bernkop-Schnürch A (2025) Biomedical applications of functional hydrogels: innovative developments, relevant clinical trials and advanced products. Biomaterials 312:122718. https://doi.org/10.1016/j.biomaterials.2024.12271810.1016/j.biomaterials.2024.122718 ↗
36. Schönlein R, Bhattarai P, Raef M, Larrañaga X, Poudel A, Biggs M et al (2025) Piezoelectric polylactic acid-based biomaterials: fundamentals, challenges and opportunities in medical device design. Biomaterials 324:123522. https://doi.org/10.1016/j.biomaterials.2025.12352210.1016/j.biomaterials.2025.123522 ↗
37. Lu Y, Pan Q, Gao W, Pu Y, Luo K, He B et al (2022) Leveraging disulfiram to treat cancer: mechanisms of action, delivery strategies, and treatment regimens. Biomaterials 281:121335. https://doi.org/10.1016/j.biomaterials.2021.12133510.1016/j.biomaterials.2021.121335 ↗
38. Hu J, Zhu J, Chen T, Zhao Y, Xu Q, Wang Y (2024) Cuproptosis in cancer therapy: mechanisms, therapeutic application and future prospects. J Mater Chem B 12(47):11226–12191. https://doi.org/10.1039/d4tb01877j10.1039/d4tb01877j ↗
39. He Y, Lin J, Huang C, Bao Q, Hao Z, Zhao S et al (2025) Virus‐Inspired Nanoparticles for Intensified Cancer Therapy via Cascade Reinforcement of “Nontoxicity‐to‐Toxicity” Transition and Mitochondrial Dysfunction. Adv Healthc Mater. https://doi.org/10.1002/adhm.20240527410.1002/adhm.202405274 ↗
40. Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S et al (2013) Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 7(7):5858–5869. https://doi.org/10.1021/nn401079610.1021/nn4010796 ↗
41. Chen H, Luo Q, Wang J, He H, Luo W, Zhang L et al (2020) Response of pH-sensitive doxorubicin nanoparticles on complex tumor microenvironments by tailoring multiple physicochemical properties. ACS Appl Mater Interfaces 12(20):22673–22686. https://doi.org/10.1021/acsami.0c0572410.1021/acsami.0c05724 ↗
42. Niu W, Xiao Q, Wang X, Zhu J, Li J, Liang X et al (2021) A biomimetic drug delivery system by integrating grapefruit extracellular vesicles and doxorubicin-loaded heparin-based nanoparticles for glioma therapy. Nano Lett 21(3):1484–1492. https://doi.org/10.1021/acs.nanolett.0c0475310.1021/acs.nanolett.0c04753 ↗
43. Wang Z, Zhou H, Su Q, Qiu Q, Deng W, Zhang M et al (2025) Morphology– and adhesion–dual biomimetic nanovaccine boosts antigen cross-presentation through subcellular transport regulation. Sci Adv 11(31):eadx6732. https://doi.org/10.1126/sciadv.adx673210.1126/sciadv.adx6732 ↗
44. Luo W, Wen G, Yang L, Tang J, Wang J, Wang J et al (2017) Dual-targeted and pH-sensitive doxorubicin prodrug-microbubble complex with ultrasound for tumor treatment. Theranostics 7(2):452–465. https://doi.org/10.7150/thno.1667710.7150/thno.16677 ↗
45. Wang J, Yang Y, Zhang Y, Huang M, Zhou Z, Luo W et al (2016) Dual-targeting heparin-based nanoparticles that re-assemble in blood for glioma therapy through both anti-proliferation and anti-angiogenesis. Adv Funct Mater 26(43):7873–7885. https://doi.org/10.1002/adfm.20160281010.1002/adfm.201602810 ↗
46. Wang Y, Li Y, Wang D, Hong S, Wang J, Xie B et al (2016) Response of heterogeneous cancer cells on targeted nanoparticles. Nanomedicine Nanotechnol Biol Med 12(7):2127–2137. https://doi.org/10.1016/j.nano.2016.05.01510.1016/j.nano.2016.05.015 ↗
47. Hu D, Zhang M, Xu Y, Xu J, Zhu J (2025) Ultra-stable metal halide perovskite nanocrystals with controllable dimension by block copolymer micelle templates. Small. https://doi.org/10.1002/smll.20250611110.1002/smll.202506111 ↗
48. Wang X, Han X, Tian X, Lee H, Xiang C, Wang C et al (2025) Regioisomeric engineering of sterically hindered bright near-infrared paraptosis agents for chemo-photodynamic therapy. J Am Chem Soc. https://doi.org/10.1021/jacs.5c1000510.1021/jacs.5c10005 ↗
49. Guo J, Wang X, Ni C, Wan X, Hu J (2022) SulfoxFluor-enabled deoxyazidation of alcohols with NaN 3. Nat Commun 13(1):2752. https://doi.org/10.1038/s41467-022-30132-x10.1038/s41467-022-30132-x ↗
50. Zheng X, Xu J, Lin R, He Y, Yu Y, Zhang Y et al (2023) Internal driving mechanism of microbial community and metabolic pathway for psychrophilic anaerobic digestion by microbial electrolysis cell. Bioresour Technol 374:128764. https://doi.org/10.1016/j.biortech.2023.12876410.1016/j.biortech.2023.128764 ↗
51. Geerdink JX, van der Wal G, de Jong LAA, Olyslager EJH, van den Goorbergh TW, Kluijtmans LAJ et al (2025) Sodium azide (NaN3) intoxication, “the man who lived”: potential effective antidote and treatment strategy. Critical Care (London, England) 29(1):103. https://doi.org/10.1186/s13054-025-05330-w10.1186/s13054-025-05330-w ↗
52. Wang D, Chernov AV, Lam R, Wang H, Li W, Li X et al (2025) Neuron-targeted caveolin-1 overexpression attenuates cognitive loss and pathological transcriptome changes in symptomatic Alzheimer’s disease models. Signal Transduct Target Ther 10(1):112–172. https://doi.org/10.1038/s41392-025-02258-z10.1038/s41392-025-02258-z ↗
53. Badaut J, Blochet C, Obenaus A, Hirt L (2024) Physiological and pathological roles of caveolins in the central nervous system. Trends Neurosci 47(8):651–664. https://doi.org/10.1016/j.tins.2024.06.00310.1016/j.tins.2024.06.003 ↗
54. Wolfe AR, Cui T, Baie S, Corrales-Guerrero S, Webb A, Castro-Aceituno V (2024) Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions. Sci Adv 10(9):eadj3551. https://doi.org/10.1126/sciadv.adj355110.1126/sciadv.adj3551 ↗
55. Lynn AY, Shin K, Eaton DA, Rose M, Zhang X, Ene M et al (2025) Investigation of the protein corona and biodistribution profile of polymeric nanoparticles for intra-amniotic delivery. Biomaterials 320:123238. https://doi.org/10.1016/j.biomaterials.2025.12323810.1016/j.biomaterials.2025.123238 ↗
56. Koshrovski-Michael S, Ajamil DR, Dey P, Kleiner R, Tevet S, Epshtein Y et al (2024) Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin–expressing cancers. Sci Adv 10(50):eadr4762. https://doi.org/10.1126/sciadv.adr476210.1126/sciadv.adr4762 ↗